8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 31, 2007

BRUKER BIOSCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation) 000-30833
(Commission
File Number) 04-3110160
(IRS Employer
Identification No.)

40 Manning Road Billerica, MA	01821
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:  (978) 663-3660

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act
oSoliciting material pursuant to Rule 14a-12 of the Exchange Act
oPre-commencement communications pursuant to Rule 14d-2(b) Exchange Act
oPre-commencement communications pursuant to Rule 13e-4(c) Exchange Act

Section 2 — Financial Information

Item 2.02.  Results of Operations and Financial Condition

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On July 31, 2007, Bruker BioSciences Corporation issued a press release announcing financial results as of and for the three and six months ended June 30, 2007.  A copy of the press release is attached hereto as Exhibit 99.1.

2

Section 9 — Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

(d)    Exhibits

Number
99.1	Press release dated July 31, 2007.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER BIOSCIENCES CORPORATION (Registrant)
	By:	/s/ Frank H. Laukien
Date: July 31, 2007		Frank H. Laukien, Ph.DChief Executive Officer and President

4

Exhibit Index

Exhibit Number	Exhibit Name	Location
99.1	Press release dated July 31, 2007.	Furnished herewith*

*Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

5

EX-99.1

Exhibit 99.1

Bruker BioSciences Reports Strong Revenue and Net Income Growth in the Second Quarter of 2007

BILLERICA, Mass., July 31, 2007 (BUSINESS WIRE)  —  Bruker BioSciences Corporation (NASDAQ: BRKR) today reported financial results for the three and six months ended June 30, 2007.

For the second quarter of 2007, revenue increased by 21% to $121.7 million, compared to revenue of $100.5 million in the second quarter of 2006.  Excluding the effects of foreign currency translation, second quarter 2007 revenue increased by 17% year-over-year.  Net income in the second quarter of 2007 was $5.0 million, or $0.05 per diluted share, compared to net income of $2.5 million, or $0.02 per diluted share, in the second quarter of 2006.

For the six months ended June 30, 2007, revenue increased by 19% to $232.2 million, compared to revenue of $195.3 million during the six months ended June 30, 2006.  Excluding the effects of foreign currency translation, revenue for the six months ended June 30, 2007 increased by 14% year-over-year.  Net income during the six months ended June 30, 2007 was $8.8 million, or $0.08 per diluted share, compared to net income of $5.8 million, or $0.06 per diluted share, during the six months ended June 30, 2006.

“The combination of our innovative products and solutions and favorable market dynamics enabled us to deliver solid increases in revenue and net income,” said Frank Laukien, President and Chief Executive Officer, when commenting on the quarter.  “We are very pleased with our second quarter 2007 year-over-year currency-adjusted revenue growth rate of 17%, which included an accelerating organic growth rate of 12% year-over-year.  Moreover, new product introductions from both our core businesses and recent acquisitions have further strengthened our position as a leader in high-performance life-science and analytical systems, and have contributed to our very healthy backlog, which positions us well for the second half of 2007.”

EARNINGS CONFERENCE CALL

Bruker BioSciences will host an operator-assisted earnings conference call at 9 a.m. Eastern Time on Tuesday, July 31, 2007.  To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol.  The webcast will be available through the Company web site for 30 days.  Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada.  Investors should refer to the Bruker BioSciences Quarterly Earnings Call.  A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 72671589.

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc.  Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis and spark-OES tools.  Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of chemical, biological, radiological and nuclear (CBRN) detection products for homeland security.  Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology.  For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our reorganization strategies, risks related to the integration of businesses we have acquired or may acquire in the future,  technological approaches, product development, market acceptance, cost and pricing of our products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and  our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Condensed consolidated statements of operations and balance sheets follow for Bruker BioSciences Corporation.

2

Bruker BioSciences Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data; unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2007		2006		2007			2006
Product revenue	$	106,646	$	88,335	$	202,008		$	172,176
Service revenue	14,959		11,899		29,950			22,270
Other revenue	78		249		232			893
Total revenue	121,683		100,483		232,190			195,339
Cost of product revenue	58,790		48,042		106,601			92,755
Cost of service revenue	9,862		6,218		19,930			12,605
Total cost of revenue	68,652		54,260		126,531			105,360
Gross profit margin	53,031		46,223		105,659			89,979
Operating Expenses:
Sales and marketing	24,088		20,900		47,852			39,732
General and administrative	7,988		6,473		15,480			13,080
Research and development	13,926		12,284		27,539			24,559
Acquisition related charges	—		3,692		—			4,868
Total operating expenses	46,002		43,349		90,871			82,239
Operating income	7,029		2,874		14,788			7,740
Interest and other income (expense), net	319		2,332		(206		)	4,013
Income before income tax provision and minority interest in consolidated subsidiaries	7,348		5,206		14,582			11,753
Income tax provision	2,323		2,623		5,590			5,863
Income before minority interest in consolidated subsidiaries	5,025		2,583		8,992			5,890
Minority interest in consolidated subsidiaries	60		45		146			93
Net income	$	4,965	$	2,538	$	8,846		$	5,797
Net income per share:
Basic	$	0.05	$	0.03	$	0.09		$	0.06
Diluted	$	0.05	$	0.02	$	0.08		$	0.06
Weighted average shares outstanding:
Basic	104,183		101,456		103,505			101,430
Diluted	106,798		101,869		106,186			101,779

3

Bruker BioSciences Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

	June 30,		December 31,
	2007		2006
	(unaudited)
ASSETS
Current assets:
Cash and short-term investments	$	41,933	$	52,147
Accounts receivable, net	72,171		79,604
Due from affiliated companies	2,666		9,028
Inventories	169,895		134,504
Other current assets	24,995		19,461
Total current assets	311,660		294,744
Property and equipment, net	95,035		90,349
Intangible and other assets	53,791		48,094
Total assets	$	460,486	$	433,187
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings	$	10,660	$	21,857
Accounts payable	27,597		23,102
Due to affiliated companies	5,773		5,901
Other current liabilities	140,992		144,268
Total current liabilities	185,022		195,128
Long-term debt	22,299		22,863
Other long-term liabilities	31,130		23,491
Minority interest in subsidiaries	385		239
Total shareholders' equity	221,650		191,466
Total liabilities and shareholders' equity	$	460,486	$	433,187

4

FOR FURTHER INFORMATION:	Michael Willett, Investor Relations Officer
	Tel: (978) 663-3660, ext. 1411 Email: Michael.Willett@Bruker.com

5